门冬胰岛素30与人胰岛素30R治疗2型糖尿病临床比较

目的:比较门冬胰岛素30与人胰岛素30R治疗2型糖尿病的疗效及低血糖风险。方法:81例2型糖尿病患者随机分为门冬胰岛素30组与人胰岛素30R组,在口服瑞格列奈1.5mg/d基础上,采用每日早晚皮下注射门冬胰岛素30与人胰岛素30R,进行为期4周的观察。比较4周后两组8个时点血糖,糖化血红蛋白(HbA1c)、低血糖事件的差异。结果:门冬胰岛素30组与人胰岛素30R组治疗后血糖较治疗前均明显下降,门冬胰岛素30组早晚餐后2h血糖低于人胰岛素30R组,差异有统计学意义(P<0.05),门冬胰岛素30组低血糖发生次数低于人胰岛素30R组,但差异无统计学意义(P>0.05),糖化血红蛋白水平无统计学差异。结论:对于2型糖尿病患者,每日两次注射门冬胰岛素30较人胰岛素30R对餐后2h血糖控制更有效,减少低血糖风险,为患者提供更灵活的用餐时间。

Comparison of the Effect and Safety between Premixed Insulin Aspart 30 and Human Insulin Premix 70/30 in the Patients with type 2 Diabetes

Objective:To compare the effect and safety between premixed insulin aspart 30 and human insulin premix 70/30 in the patients with type 2 diabetes.Methods: 81 patients with type 2 diabetes were randomly divided into groups of receiving premixed insulin aspart 30 and human insulin premix 70/30 for 4 weeks.Blood glucose and HbA1c were measured and compared before and after the insulin treatments.Results:After the treatments,2 hours postprandial glucose levels after breakfast and dinner were significantly decreased(P<0.05).However,HbA1c and the risk of hypoglycaemia did not differ significantly between the treatments.Conclusion: Treatment of diabetic patients with premixed insulin aspart 30 can more significantly improve 2 hours postprandial blood glucose level compared to treatment with human insulin premix 70/30,without increasing the risk of hypoglycaemia.